Parasitology Research

, Volume 97, Issue 6, pp 445–451 | Cite as

Evaluation of silymarin in the treatment on asymptomatic Giardia infections in dogs

  • Seung-Ki Chon
  • Nam-Soo Kim
Original Paper


We have reported previously the efficacy of antiprotozoal drugs against canine giardiasis (In press, Journal of Veterinary Clinic, the Korean Society of Veterinary Clinics). Fenbendazole was found to be the most efficacious for the treatment of canine giardiasis. There were no significant differences between the efficacy of albendazole and fenbendazole against canine giardiasis. On the other hand, the efficacy of metronidazole for the treatment of canine giardiasis, the efficacy was lower when compared to that of albendazole and fenbendazole. On the basis of these results, to evaluate clinical effect of silymarin, we evaluated the therapeutic efficacy of metronidazole alone, or combined with silymarin for 2 weeks for canine giardiasis. In addition, to observe effects on nutrition, we investigated the changes of body weight, the serum biochemical indicators for liver inflammation (GOT, GPT, NH3), the liver cell regeneration indicators (total protein, albumin) and the hematological changes during treatment (WBC, RBC, MCV, MCH and MCHC). The dogs were allocated to four groups; one group was treated with silymarin (3.5 mg/kg once a day, oral), another with metronidazole (50 mg/kg once a day, oral), and the other group with silymarin (3.5 mg/kg once a day, oral) plus metronidazole (50 mg/kg once a day, oral), while control group remained nontreated. The fecal samples from all the dogs were examined, using the ZSCT and giardia antigen test kit (SNAP* Giardia, IDEXX Laboratories), from each dog of each group for three times a week for 2 weeks. Dogs were considered to have giardiasis when one or more of the fecal samples had positive results for Giardia cysts. Seven days after treatment, the efficacy of silymarin plus metronidazole was found 79%, whereas that of metronidazole was 72%. Ten days post-treatment the efficacy of metronidazole plus silymarin (91%) was significantly different in comparison with that of metronidazole (75%). Two weeks post-treatment no cysts were detected in the fecal samples in the dogs of metronidazole or silymarin plus metronidazole-treated groups. Whereas, the fecal samples of all the dogs of the control and only silymarin-treated groups were giardia positive. Signs of side effects were not observed in silymarin plus metronidazole-treated dogs. But poor appetite and intermittent vomiting signs were observed in two dogs of the metronidazole-treated group that resolved when metronidazole administration was discontinued. The body weight of those treated with metronidazole was significantly decreased in comparison with those treated with silymarin and metronidazole plus silymarin. There were significant differences of body weight between the dogs treated with silymarin and metronidazole. Two weeks after metronidazole treatment, serum concentration of GOT, GPT and NH3 were significantly increased in comparison with those treated with silymarin. On the other hand, the serum concentration of GOT, GPT and NH3 were not significantly increased when treated with silymarin plus metronidazole compared to those treated with metronidazole. Serum total protein and albumin concentrations were decreased after metronidazole treatment as compared to those treated with silymarin and silymarin plus metronidazole. The concentrations of serum total protein and albumin decreased significantly in metronidazole-treated group as compared to that of treated with silymarin. The numbers of WBC and RBC did show significant differences in the dogs treated with metronidazole, while MCV, MCH were significant by different between silymarin and metronidazole-treated dogs. On the other hand, there were no significant differences in MCHC in any groups. These data suggest that silymarin, in supplement with antiprotozoal drugs, can influence the therapy of canine giardiasis.


Metronidazole Fecal Sample Albendazole Silymarin Mean Corpuscular Volume 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abe N, Read C, Thompson RC, Iseki M (2005) Zoonotic genotype of Giardia intestinalis detected in a ferret. J Parasitol 91:179–182PubMedGoogle Scholar
  2. Barr SC (1998) Enteric protozoal infections. In: Greene CE (ed) Infectious disease of the dog and cat, 2nd edn. WB Saunders Co, Philadelphia, pp 482–491Google Scholar
  3. Barr SC, Bowman DD, Heller RL (1994) Efficacy of fenbendazole against giardiasis in dogs. Am J Vet Res 55:988–990PubMedGoogle Scholar
  4. Barr SC, Bowman DD, Heller RL (1993) Efficacy of albendazole against giardiasis in dogs. Am J Vet Res 54:926–928PubMedGoogle Scholar
  5. Beale BS, Goring RL, Schaer M, Robertson SA (1991) Surgical treatment of perforating duodenal ulcer in a dog by use of modified choledochoduodenostomy and gastrojejunostomy. J Am Vet Med Assoc 198:281–285PubMedGoogle Scholar
  6. Bell CA, Dykstra CC, Naiman NA, Cory M, Fairley TA, Tidwell RR (1993) Structure-activity studies of dicationically substituted bis-benzimidazoles against Giardia lamblia: correlation of antigiardial activity with DNA binding affinity and giardial topoisomerase II inhibition. Antimicrob Agents Chemother 37:2668–2673PubMedGoogle Scholar
  7. Boothe DM (1990) Drug therapy in cat: a therapeutic category approach. J Am Vet Med Assoc 196:1659–1669PubMedGoogle Scholar
  8. Caylor KB, Cassimatis MK (2001) Metronidazole neurotoxicosis in two cats. J Am Anim Hos Assoc 37:258–262Google Scholar
  9. Chander R, Kapoor NK, Dhawan BN (1989) Hepatoprotective activity of silymarin against hepatic damage in Mastomys natalensis infected with Plasmodium berghei. Indian J Med Res 90:472–477PubMedGoogle Scholar
  10. Chon SK, Kim NS (2005) The efficacy of albendazole, fenbendazole and metronidazole for treatment of Canine Giardia. J Vet Clin (in processing)Google Scholar
  11. Dewick PM (1997) Medical natural products. Wiley, New York, pp 138–140Google Scholar
  12. Dow SW (1988) Management of anaerobic infections. Vet Clin North Am Sm Anim Pract 18:1167–1182Google Scholar
  13. Dow SW, LeCouteur RA, Poss ML, Beadleston D (1989) Central nervous system toxicosis associated with metronidazole treatment of dog: five cases (1984–1987). J Am Vet Med Assoc 195:365–368PubMedGoogle Scholar
  14. Dubey JP (1993) Intestinal protozoa infections. Vet Clin North Am Sm Anim Pract 23:37–55Google Scholar
  15. Eilice FP (1952) Studies on the cytology and life history of a Giardia from the laboratory rat. Univ Calif Publ Zool 57:53–143Google Scholar
  16. Finch R, Moore M, Roen D (1992) A warning to clinicians: metronidazole neurotoxicity in a dog. Prog Vet Neurol 2:307–309Google Scholar
  17. Gazak R, Svobodova A, Psotova J, Sedmera P, Prikrylova V, Walterova D, Kren V (2004) Oxidised derivatives of silybin and their antiradical and antioxidant activity. Bioorg Med Chem 12:5677–5687CrossRefPubMedGoogle Scholar
  18. Georgi JR, Georgi ME, Theodorides VJ (1990) Parasitology for veterinarians, 5th edn. WB Saunders Co, Philadelphia, pp 268–269Google Scholar
  19. Giangaspero A, Paoletti B, Iorio R, Traversa D (2005) Prevalence and molecular characterization of Giardia duodenalis from sheep in central Italy. Parasitol Res 96(1):32–37CrossRefPubMedGoogle Scholar
  20. Graczyk RC, Thompson RCA, Fayer R, Adams P, Morgan UM, Lewis EJ (1999) Giardia duodenalis of genotype A recovered from clams in the Chesapeake Bay subestuary, Rhode River. Am J Trop Med Hyg 61:526–529PubMedGoogle Scholar
  21. Grant J, Mahanty S, Khadir A, MacLean JD, Kokoskin E, Yeager B, Joseph L, Diaz J, Gotuzzo E, Mainville N, Ward BJ (2001) Wheat germ supplement reduces cyst and trophozoite passage in people with giardiasis. Am J Trop Med Hyg 65:705–710PubMedGoogle Scholar
  22. Gupta OP, Sing S, Bani S, Sharma N, Malhotra S, Gupta BD, Banerjee SK, Handa SS (2000) Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine 7:21–24PubMedGoogle Scholar
  23. Hwang JM, Wang CJ, Chou FP, Tseng TH, Hsieh YS, Lin WL, Chu CY (2002) Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver. Arch Toxicol 76:664–670CrossRefPubMedGoogle Scholar
  24. Jergens AE (1999) Inflammatory bowel disease: current perspectives. Vet Clin North Am Sm Anim Pract 29:501–521Google Scholar
  25. Kirkpatrick CE (1987) Giardiasis. Vet Clin North Am Sm Anim Pract 17:1377–1387Google Scholar
  26. Kirkpatrick CE (1988) Epizootiology of endoparasitic infections in pet dogs and cats presented to a veterinary teaching hospital. Vet Parasitol 30:113–124CrossRefPubMedGoogle Scholar
  27. Lalle M, Jimenez-Cardosa E, Caccio SM, Pozio E (2005) Genotyping of Giardia duodenalis from humans and dogs from Mexico using a beta-giardin nested polymerase chain reaction assay. J Parasitol 91:203–205PubMedGoogle Scholar
  28. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM (2003) Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 37:336–339CrossRefPubMedGoogle Scholar
  29. Liu CL, Wang JM, Chu CY, Cheng MT, Tseng TH (2002) In vivo protective effect of protocatechuic acid on tert-butyl hydroperoxide-induced rat hepatotoxicity. Food Chem Toxicol 40:635–641CrossRefPubMedGoogle Scholar
  30. Luper S (1998) A review of plant used in the treatment of liver diseases: part 1. Altern Med Rev 3:410–424PubMedGoogle Scholar
  31. Marshall MM, Naumovitz D, Ortega Y, Sterling CR (1997) Waterborne protozoan pathogens. Clin Microbiol Rev 10:67–85Google Scholar
  32. Pepping J (1999) Milk tistle: Silibum marianum. Am J Health Syst Pharm 56:1195–1197PubMedGoogle Scholar
  33. Perez-Victoria JM, Perez-Victoria FJ, Conseil G, Maitrejean M, Comte G, Barron D, Di Pietro A, Castanys S, Gamarro F (2001) High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin. Antimicrob Agents Chemother 45(2):439–446CrossRefPubMedGoogle Scholar
  34. Perkins SE, Yan LL, Shen Z, Hayward A, Murphy JC, Fox JG (1996) Use of PCR and culture to detect Helicobacter pyroli in naturally infected cats following triple antimicrobial therapy. Antimicrob Agents Chemother 40:1486–1490PubMedGoogle Scholar
  35. Petmitr PC, Ramdja M, Kajomdechakiat S (2000) In vitro sensitivity of Trichomonas vaginalis to DNA topoisomerase II inhibitors. Southeast Asian J Trop Med Public Health 31(1):118–122PubMedGoogle Scholar
  36. Plumb DC (1999) Veterinary drug handbook, 3rd edn. Iowa State Univ Press, Ames, pp 424–427Google Scholar
  37. Saija A, Scalese M, Lanza M, Marzullo D, Bonina F, Castelli F (1995) Flavonoids as antioxidant agents: importance of their interaction with biomembranes. Free Radic Biol Med 19:481–486CrossRefPubMedGoogle Scholar
  38. Saxon B, Magne ML (1993) Reversible central nervous system toxicosis associated with metronidazole therapy in three cats. Prog Vet Neurol 4:25–27Google Scholar
  39. Stokol T, Randolph JF, Nachbar S, Rodi C, Barr SC (1997) Development of bone marrow toxicosis after albendazole administration in a dog and cat. J Am Vet Med Assoc 210:1753–1756PubMedGoogle Scholar
  40. Taboada J, Dimski DS (1995) Hepatic encephalopathy: clinical signs, pathogenesis, and treatment. Vet Clin North Am Sm Anim Pract 25:337–355Google Scholar
  41. Thompson RCA, Hopkins RM, Homan WL (2000) Nomenclature and genetic groupings of Giardia infecting mammals. Parasitol Today 16:210–213CrossRefPubMedGoogle Scholar
  42. Tjalve H (1997) Adverse reactions to veterinary drugs reported in Sweden during 1991–1995. J Vet Pharmacol Ther 20:105–110CrossRefPubMedGoogle Scholar
  43. Tracy JW, Webster LT (1996) Dugs used in the chemotherapy of protozoal infections. In: Hardman JG, Limbird LE (eds) Goodman & Gilman’s the pharmacologic basis of therapeutics, 9th edn. McGraw Hill, New York, pp 987–1008Google Scholar
  44. Tsuchiya H (1931) The localization of Giardia canis (Hegner, 1922) as affected by diet. J Parasitol 18:232–246Google Scholar
  45. Wagner H, Seligmann O, Lotter H (1985) In: Farkas L, Gabor M and Kellay F (eds) Recent advances in the chemistry, Stereochemistry, synthesis and pharmacology of flavoligans, flavonoids and bioflavonoids. Elsevier, New York, p 139Google Scholar
  46. Wellington K, Jarwis B (2001) Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15:465–489PubMedGoogle Scholar
  47. Zimmer JF, Burrington DB (1986) Comparison of four protocols for the treatment of canine giardiasis. J Am Anim Hosp Assoc 22:168–172Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Chon Seung Ki Animal ClinicChonjeSouth Korea
  2. 2.Department of Veterinary MedicineChonbuk National University Chonju South Korea

Personalised recommendations